Broad-Spectrum COVID-19 Antibody Therapy

Aseem Healthcare is pleased to announce we have identified a cocktail of highly potent, neutralizing antibodies to SARS-COV2. Our results as benchmarked to competing platforms show better neutralizing activity then currently approved products, Regeneron, Eli Lilly and Gsk/Vir when used in combination.

When the pandemic first began, no specific treatment for COVID-19 existed. Since this time, however, the FDA has granted Emergency Use Authorization (EUA) to several monoclonal antibody therapies as a treatment for COVID-19 as well as newly approved antiviral pills from Pfizer and Merck.

For the first wave of the pandemic there was little clinicians could do against the virus beyond a “wait and see” approach for those who tested positive. The treatment paradigm was focused on managing the complications of the infection via oxygen therapy and other methods. The ideal scenario is to prevent a patient from getting to the stage of severe respiratory distress.

Our monoclonal antibody (mAb) therapy aims to tackle this issue in individuals who are elevated risk, including those who have been vaccinated.


As strains change and people age, their immune systems are left less and less likely to fight off Covid 19. Like other respiratory viruses SARS-COV-2 is unfortunately ‘here to stay’, and monoclonal antibody (mAb) treatments will be crucial in reducing disease severity, which in turn will take the pressure of healthcare systems by preventing the back log of hospital beds and clinical staff that are needed to look after severely ill Covid patients. Reliance on vaccines is not enough and the ‘knock-on’ effect to primary and secondary care from the increase in hospitalizations is what is driving the constant lockdowns, which result in further instability across all sectors of the economy. This ‘knock-on’ effect is what makes Covid-19 so dangerous, not just from a public health perspective, but in a broader socioeconomic sense. To effectively manage this outbreak, the Covid-19 treatment paradigm needs to include a multi-pronged approach of mAb therapies, boosters and antiviral pills.
-Khelan Patel (Chief Commercial Officer, Aseem Healthcare)

Target Product Profile for AH-5-COV antibody cocktail

Our SARS-CoV-2 (COVID-19) mAb therapeutic program is entering Investigational New Drug (IND) enabling development. A summary of the target product profile for our cocktail is below:

  • Broad neutralisation against all variants tested including South African, Indian and Brazilian strains – we are currently testing against the new Omicron variant and believe we will have good efficacy against this strain
  • Ongoing studies to improve thermostability, and extend half-life to support bioavailability and efficacy
  • Ongoing safety studies to design to prevent immunotoxicity (fully human IgG backbone)
  • Evergreening strategies to develop formulations that support better patient compliance (intramuscular, Sub Cutaneous and inhalable)
COVID-19 mAb antibody therapy
bacteriophage studies
error: Content is protected !!